Division of Cardiovascular Medicine, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA.
Adult Survivorship Program, Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, 450 Brookline Avenue, Boston, MA 02215, USA.
Eur Heart J Qual Care Clin Outcomes. 2020 Oct 1;6(4):315-322. doi: 10.1093/ehjqcco/qcaa015.
The prognostic importance of post-diagnosis assessment of cardiorespiratory fitness (CRF) in cancer patients is not well established. We sought to examine the association between CRF and mortality in cancer patients.
This was a single-centre cohort analysis of 1632 patients (58% male; 64 ± 12 years) with adult-onset cancer who were clinically referred for exercise treadmill testing a median of 7 [interquartile range (IQR): 3-12] years after primary diagnosis. Cardiorespiratory fitness was defined as peak metabolic equivalents (METs) achieved during standard Bruce protocol and categorized by tertiles. The association between CRF and all-cause and cause-specific mortality was assessed using multivariable Cox proportional hazard models adjusting for important covariates. Median follow-up was 4.6 (IQR: 2.6-7.0) years; a total of 411 deaths (229, 50, and 132 all-cause, cardiovascular (CV), and cancer related, respectively) occurred during this period. Compared with low CRF (range: 1.9-7.6 METs), the adjusted hazard ratio (HR) for all-cause mortality was 0.38 [95% confidence interval (CI): 0.28-0.52] for intermediate CRF (range: 7.7-10.6 METs) and 0.17 (95% CI: 0.11-0.27) for high CRF (range: 10.7-22.0 METs). The corresponding HRs were 0.40 (95% CI: 0.19-0.86) and 0.41 (95% CI: 0.16-1.05) for CV mortality and 0.40 (95% CI: 0.26-0.60) and 0.16 (95% CI: 0.09-0.28) for cancer mortality, respectively. The adjusted risk of all-cause, CV, and cancer mortality decreased by 26%, 14%, and 25%, respectively with each one MET increment in CRF.
Cardiorespiratory fitness is a strong, independent predictor of all-cause, CV, and cancer mortality, even after adjustment for important clinical covariates in patients with certain cancers.
癌症患者诊断后评估心肺功能(CRF)的预后重要性尚未得到充分证实。我们旨在研究 CRF 与癌症患者死亡率之间的关系。
这是一项单中心队列分析,纳入了 1632 名(58%为男性;64±12 岁)成年期癌症患者,这些患者在初次诊断后中位数 7[四分位距(IQR):3-12]年时因临床需要接受运动平板测试。心肺功能通过标准 Bruce 方案中达到的最大代谢当量(METs)定义,并按三分位进行分类。使用多变量 Cox 比例风险模型评估 CRF 与全因和病因特异性死亡率之间的关系,调整了重要协变量。中位随访时间为 4.6[IQR:2.6-7.0]年;在此期间,共有 411 例死亡(229 例、50 例和 132 例分别为全因、心血管(CV)和癌症相关死亡)。与低 CRF(范围:1.9-7.6 METs)相比,全因死亡率的调整后危险比(HR)为 0.38[95%置信区间(CI):0.28-0.52],中 CRF(范围:7.7-10.6 METs)为 0.17(95% CI:0.11-0.27),高 CRF(范围:10.7-22.0 METs)为 0.17(95% CI:0.11-0.27)。CV 死亡率的相应 HR 分别为 0.40[95% CI:0.19-0.86]和 0.41[95% CI:0.16-1.05],癌症死亡率分别为 0.40[95% CI:0.26-0.60]和 0.16[95% CI:0.09-0.28]。CRF 每增加 1 MET,全因、CV 和癌症死亡率的调整风险分别降低 26%、14%和 25%。
即使在调整了某些癌症患者的重要临床协变量后,CRF 仍然是全因、CV 和癌症死亡率的强有力、独立预测因素。